Advertisement

Topics

Ablynx nv Company Profile

00:35 EST 22nd November 2017 | BioPortfolio

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therapeutic targets that are inaccessible to conventional antibodies. Nanobodies™ therefore address the strong and growing demand for improved therapeutics for serious and life-threatening diseases, and have the potential to create new market opportunities beyond those accessible to conventional antibodies.
Since commencing operations in 2002, Ablynx has generated Nanobody™ leads against a number of human disease targets across a wide range of therapeutic areas. Two of these leads are now in advanced pre-clinical development, and Ablynx’s first therapeutic program is expected to enter human clinical trials in 2006.

Ablynx’s Nanobody™ technology was originally discovered at laboratories of the Free University of Brussels (VUB). Scientists at the VUB discovered that up to half of the antibody repertoire in camelidae consists of antibodies that lack a conventional antibody light-chain, but retain full antigen-binding capacity. The technology and intellectual property created around this discovery was further developed within the Flanders Interuniversity Institute for Biotechnology (VIB). In 2001 VIB created Ablynx in collaboration with founding venture investor, GIMV. Ablynx now operates from its state-of-the-art facilities in Ghent, Belgium.

Location

Technologiepark 4
Ghent
Zwijnaarde
9052
Belgium

Contact

Phone: 32 9 261.06.32
Fax: 32 9 261.06.28
Email: info@ablynx.com


News Articles [103 Associated News Articles listed on BioPortfolio]

Ablynx: ABLYNX CLOSES $200 MILLION INITIAL PUBLIC OFFERING IN THE UNITED STATES

REGULATED INFORMATION GHENT, Belgium, 27 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX], a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody platform ...

Ablynx: ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING

REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 17 October 2017 - Ablynx NV [Euronext Brussels: ABLX; OTC: ABYLY], a late-stage clinical biopharmaceutical company utilising its propriet...

Ablynx enters $2.8bn Nanobody deal with Sanofi

Sanofi is Ablynx NV’s latest Big Pharma partner through a new deal involving Ablynx’s Nanobodies that could be worth up to $2.8bn to the biotech.

Ablynx: ABLYNX CLOSES ON UNDERWRITERS' OPTION TO PURCHASE $30 MILLION OF ADDITIONAL SHARES IN THE U.S. INITIAL PUBLIC OFFERING

REGULATED INFORMATION GHENT, Belgium, 30 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX], a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody platform ...

Ablynx: ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES

REGULATED INFORMATION GHENT, Belgium, 20 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a research collaboration and global exclusive licensing a...

Ablynx’s Success Story: The Past, Present and Future

Fintan Walton talks to Edwin Moses, CEO of Ablynx, about the success that the company has enjoyed since its inception, and his plans for it going forward. Edwin talks about the importance of location ...

Ablynx: SUSPENSION OF TRADING IN ABLYNX SHARES ON EURONEXT BRUSSELS

REGULATED INFORMATION GHENT, Belgium, 25 October 2017 (1 pm CEST) - Trading in the shares of Ablynx NV [Euronext Brussels: ABLX; OTC: ABYLY] was suspended at the request of the Company on 25 Octob...

Ablynx Banks $200M IPO in Nasdaq Debut

Ablynx announced the price of its U.S. IPO at $17.50.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Ablynx nv

Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies™. The structure and extreme stability of Nanobodies™ enables them to engage therap...

More Information about "Ablynx nv" on BioPortfolio

We have published hundreds of Ablynx nv news stories on BioPortfolio along with dozens of Ablynx nv Clinical Trials and PubMed Articles about Ablynx nv for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ablynx nv Companies in our database. You can also find out about relevant Ablynx nv Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record